MINAPHARM Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
MINAPHARM Pharmaceuticals has been growing earnings at an average annual rate of 20.6%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 17.1% per year.
Key information
20.6%
Earnings growth rate
22.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 17.1% |
| Return on equity | 0.6% |
| Net Margin | -1.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MINAPHARM Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,892 | -55 | 726 | 151 |
| 30 Sep 23 | 3,943 | 191 | 673 | 125 |
| 30 Jun 23 | 4,003 | 461 | 603 | 98 |
| 31 Mar 23 | 3,794 | 507 | 525 | 76 |
| 31 Dec 22 | 3,621 | 590 | 472 | 59 |
| 30 Sep 22 | 3,442 | 544 | 456 | 46 |
| 30 Jun 22 | 3,212 | 467 | 429 | 46 |
| 31 Mar 22 | 3,032 | 454 | 401 | 47 |
| 31 Dec 21 | 3,005 | 448 | 386 | 46 |
| 30 Sep 21 | 2,918 | 422 | 377 | 53 |
| 30 Jun 21 | 2,754 | 398 | 357 | 46 |
| 31 Mar 21 | 2,583 | 325 | 337 | 43 |
| 31 Dec 20 | 2,361 | 285 | 327 | 39 |
| 30 Sep 20 | 2,200 | 271 | 327 | 40 |
| 30 Jun 20 | 2,115 | 216 | 312 | 39 |
| 31 Mar 20 | 2,080 | 174 | 319 | 40 |
| 31 Dec 19 | 2,051 | 141 | 311 | 39 |
| 30 Sep 19 | 1,917 | 86 | 310 | 48 |
| 30 Jun 19 | 1,936 | 67 | 304 | 52 |
| 31 Mar 19 | 1,948 | 81 | 306 | 59 |
| 31 Dec 18 | 1,919 | 116 | 291 | 65 |
| 30 Sep 18 | 1,928 | 156 | 258 | 68 |
| 30 Jun 18 | 1,820 | 186 | 247 | 65 |
| 31 Mar 18 | 1,717 | 198 | 220 | 54 |
| 31 Dec 17 | 1,646 | 175 | 209 | 53 |
| 30 Sep 17 | 1,493 | 65 | 203 | 46 |
| 30 Jun 17 | 1,325 | 55 | 193 | 41 |
| 31 Mar 17 | 1,190 | 35 | 179 | 46 |
| 31 Dec 16 | 1,035 | 33 | 173 | 39 |
| 30 Sep 16 | 1,023 | 86 | 152 | 32 |
| 30 Jun 16 | 1,019 | 97 | 146 | 34 |
| 31 Mar 16 | 1,001 | 110 | 145 | 29 |
| 31 Dec 15 | 966 | 83 | 140 | 26 |
| 30 Sep 15 | 916 | 85 | 138 | 29 |
| 30 Jun 15 | 885 | 61 | 137 | 28 |
| 31 Mar 15 | 861 | 57 | 128 | 26 |
| 31 Dec 14 | 830 | 49 | 126 | 29 |
| 30 Sep 14 | 807 | 75 | 121 | 24 |
| 30 Jun 14 | 772 | 71 | 114 | 29 |
| 31 Mar 14 | 728 | 69 | 116 | 28 |
| 31 Dec 13 | 712 | 81 | 114 | 25 |
| 30 Sep 13 | 687 | 59 | 108 | 27 |
Quality Earnings: MIPH is currently unprofitable.
Growing Profit Margin: MIPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIPH is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare MIPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (27.9%).
Return on Equity
High ROE: MIPH has a negative Return on Equity (0.64%), as it is currently unprofitable.